

Steve Sisolak  
Governor  
Richard Whitley, MS  
Director



**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
Division of Health Care Financing and Policy  
*Helping people. It's who we are and what we do.*



Suzanne Bierman, JD, MPH  
Administrator

**Silver State Script Board**

**Draft Meeting Minutes**

**Date of Meeting:** Thursday, March 25, 2021, at 1:00 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Silver State Script Board.

Agenda Item	Record	Notes																											
<b>Closed Executive Session</b>																													
Financial Review of Drug Classes with Proposed Changes	<p>Chairman Decerbo called the meeting to order at 1:09 PM on March 25, 2021.</p> <p>Roll was taken by Chairman Decerbo.</p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 15%; text-align: center;">Present</th> <th style="width: 15%; text-align: center;">Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p><b>DHCFP Staff Present were as follows:</b></p> <p>Olsen, David, Social Services Chief III</p> <p>Gudino, Antonio, Social Services Program Specialist III</p> <p>Flowers, Ellen, Program Officer I</p> <p>Lither, Gabriel, SDAG</p> <p><b>Nevada Department of Health and Human Services Staff Present were as follows:</b></p>
	Present	Absent																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											

Agenda Item	Record	Notes
	<p data-bbox="619 240 1291 267">Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/></p> <p data-bbox="619 313 898 341">A quorum was present.</p> <p data-bbox="609 399 1507 500">Chairman Decerbo directed Kevin Whittington to proceed with the Financial Review of Drugs classes with proposed changes up for review during the First Quarter 2021 Silver State Scripts Board meeting.</p> <p data-bbox="609 521 1486 621">Mr. Whittington reminded the board members the financial material presented is confidential and should not be discussed or disclosed outside of this closed session of the Silver States Script Board meeting.</p> <p data-bbox="609 643 1507 743">Mr. Whittington informed the Board the recommendation for the proposed new class Cardiovascular Agents - Antilipemics - PCSK9 Inhibitors was to defer action at this time, as such no financial review was presented.</p> <p data-bbox="609 764 1493 865">Mr. Whittington presented the Financial Review of the Hormones and Hormone Modifiers - Antidiabetic Agents - Insulin (Vials, Pens and Inhaled) class noting the products with proposed changes in PDL status.</p> <p data-bbox="609 886 1493 1019">Mr. Whittington presented the Financial Review of the Gastrointestinal Agents - Antiemetics - Serotonin-receptor antagonists/combo and Dopamine Antagonists class noting the products with proposed changes in PDL status.</p> <p data-bbox="609 1040 1493 1141">Mr. Whittington presented the Financial Review of the Cardiovascular Agents - Antihypertensive Agents - Beta-Blockers class noting the products with proposed changes in PDL status.</p> <p data-bbox="609 1162 1478 1263">Mr. Whittington presented the Financial Review of the Genitourinary Agents - Bladder Antispasmodics class noting the products with proposed changes in PDL status.</p> <p data-bbox="609 1284 1493 1385">Mr. Whittington concluded the financial reviews and Chairman Decerbo directed the Board members to transition to the open session of the Silver States Script Board Meeting.</p>	<p data-bbox="1535 240 1864 337">Slamowitz, Beth, Pharm.D., Senior Policy Advisor on Pharmacy</p> <p data-bbox="1535 375 1856 475"><b>Gainwell Technology Staff Present were as follows:</b> Leid, Jovanna, Pharm.D.</p> <p data-bbox="1535 513 1885 760"><b>OptumRx Staff Present were as follows:</b> Jeffery, Carl, Pharm.D. Whittington, Kevin, R.Ph. Hansen, Sean Earnest, Rob, Pharm.D., JD Chien, Michael, Pharm.D.</p>

Agenda Item	Record	Notes																														
<b>Open Public Meeting</b>																																
<p>1. Call to Order and Roll Call</p>	<p>Chairman Decerbo called the meeting to order at 1:35 PM on March 25, 2021.</p> <p>Roll was taken by Chairman Decerbo.</p> <table border="0" data-bbox="619 418 1354 824"> <thead> <tr> <th></th> <th>Present</th> <th>Absent</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Singh, Aditi, MD</td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>A quorum was present.</p>		Present	Absent	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p><b>DHCFP Staff Present were as follows:</b>  Olsen, David, Social Services Chief III  Gudino, Antonio, Social Services Program Specialist III  Flowers, Ellen, Program Officer I  Lither, Gabriel, SDAG</p> <p><b>Gainwell Technology Staff Present were as follows:</b>  Leid, Jovanna, Pharm.D.</p> <p><b>OptumRx Staff Present were as follows:</b>  Jeffery, Carl, Pharm.D.  Whittington, Kevin, R.Ph.  Hansen, Sean  Ernest, Rob, Pharm.D., JD</p> <p><b>The public attendee list is included as Attachment A.</b></p> <p><b>Note:</b> Participants may not have chosen to reveal their identity and in the absence of a sign-in sheet the accuracy of the attendee list is not assured.</p>
	Present	Absent																														
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
Singh, Aditi, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														

Agenda Item	Record	Notes
2. Public Comment on Any Matter on the Agenda.	<p>Telephonic and web comment was called for and the phone lines were opened.</p> <p>No public comment was offered.</p>	
3. Administrative		
a. For Possible Action: Review and Approve Meeting Minutes from January 21, 2021.	<p>No corrections were offered.</p> <p>The minutes were approved by unanimous consent.</p>	
b. Status Update by the DHCFP.	<p>Chief David Olsen introduced himself and provided a brief employment background with the State of Nevada. Chief Olsen discussed the current legislative session and the extended deadline to introduce new bills. Chief Olsen discussed the request to the Board to be on camera during voting and roll call.</p> <p>Mr. Antonio Gudino updated the Board on the coverage of the Janssen COVID-19 vaccine that received emergency use authorization and referred the public and the Board to the website where the billing information can be found. Mr. Gudino announced the availability of the electronic prior authorization system for providers to submit prior authorizations through their organization's electronic medical records system or the online portal. Mr. Gudino announced the implementation of a new rebate indicator from the Centers of Medicare and Medicaid Services which may cause some over-the-counter medications to reject for not being rebatable and referred the public to the Medicaid website for additional information.</p>	<p>Referenced web addresses:</p> <p>The Nevada Department of Health and Human Services, Division of Health Care Financing and Policy Provider Portal.  <a href="https://www.medicaid.nv.gov/">https://www.medicaid.nv.gov/</a></p> <p>The Division of Health Care Financing and Policy  <a href="http://dhcfnv.gov/">http://dhcfnv.gov/</a></p>
c. Presentation and discussion of updated Silver State Scripts Board bylaws.	<p>Chief Olsen highlighted Section Six, Item C from the presented bylaws that restrict a board member from voting to approve or disapprove an item on the agenda if they do not attend the closed executive session of the Silver State Scripts Board meeting. Chief Olsen announced other changes to the bylaws are being reviewed and will be presented at a future meeting.</p>	
4. Proposed New Drug Classes		
a. For Possible Action: Discussion and possible	<p>Dr. Jeffery recommended the Board defer action on this item at this time.</p>	

Agenda Item	Record	Notes
adoption of Cardiovascular Agents - Antilipemics - PCSK9 Inhibitors.	Chairman Decerbo agreed to defer the topic to a future meeting. No further action was taken.	
i. Public comment.	No public comment was called for.	
ii. Drug class review presentation by OptumRx.	No presentation was made on this item.	
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	No action was taken on this item.	
iv. Presentation of recommendations for PDL inclusion by OptumRx.	No presentation was made on this item.	
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	No action was taken on this item.	
5. Established Drug Classes Being Reviewed Due to the Release of New Drugs		
a. For Possible Action: Discussion and possible adoption of Hormones and Hormone Modifiers - Antidiabetic		

Agenda Item	Record	Notes																																				
Agents - Inulin (vials, Pens and Inhaled).																																						
i. Public comment.	<p>Telephonic and web comment was called for and the phone lines were opened.</p> <p>No public comment was offered.</p>																																					
ii. Drug class review presentation by OptumRx.	<p>Dr. Jeffery highlighted a new long-acting insulin, Semglee, approved through the 505(b)(2) pathway and the two clinical trials demonstrating it is non-inferior to the active comparator insulin glargine for type one and type two diabetes.</p> <p>Dr. Jeffery recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Chu seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="590 922 1522 1284"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by OptumRx.	<p>Dr. Jeffery presented the recommended changes to the class, adding Semglee as non-preferred, moving Novolin 70/30 to non-preferred, moving insulin aspart to preferred, and the rest of the class is to remain the same.</p>																																					

Agenda Item	Record	Notes																																				
<p>v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.</p>	<p>Board Member Adashek moved to accept the proposed changes.</p> <p>Board Member Chu seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="611 418 1501 776"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<p>b. For Possible Action: Discussion and possible adoption of Gastrointestinal Agents - Antiemetics - Serotonin-receptor antagonists/combo and Dopamine Antagonists.</p>																																						
<p>i. Public comment.</p>	<p>Telephonic and web comment was called for and the phone lines were opened.</p> <p>No public comment was offered.</p>																																					
<p>ii. Drug class review presentation by OptumRx.</p>	<p>Dr. Jeffery discussed the new product, Barhemsys, the mechanism of action, indication, administration, and the four placebo-controlled trials demonstrating efficacy.</p> <p>Dr. Jeffery recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					

Agenda Item	Record	Notes																																				
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Khurana seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="617 451 1457 818"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by OptumRx.	<p>Dr. Jeffery recommended adding Barhemsys as non-preferred, removing Kytril since it is no longer available on the market, and keeping the rest of the class the same.</p>																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to accept the recommendations.</p> <p>Board Member Chu seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="617 1149 1457 1388"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>													
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			



Agenda Item	Record	Notes																												
	Khurana, Sapandeeep, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Passalacqua, Brian, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>																													
6. Established Drug Classes																														
a. For Possible Action: Discussion and possible adoption of Cardiovascular Agents - Antihypertensive Agents - Beta-Blockers.																														
i. Public comment.	Telephonic and web comment was called for and the phone lines were opened.  No public comment was offered.																													
ii. Drug class review presentation by OptumRx.	Dr. Jeffery briefly discussed the differences in the beta-blocker class.  Dr. Jeffery recommended the Board consider the class clinically and therapeutically equivalent.																													
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	Board Member Khurana moved to accept the list is clinically and therapeutically equivalent.  Board Member Ward seconded the motion.  A vote was held: <table data-bbox="590 1117 1522 1399"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumbly, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumbly, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Crumbly, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
Khurana, Sapandeeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

Agenda Item	Record	Notes																																				
	Passalacqua, Brian, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>																																					
iv. Presentation of recommendations for PDL inclusion by OptumRx.	Dr. Jeffery recommended the Board move betaxolol, nadolol, and timolol to non-preferred, include the extended-release version of metoprolol as preferred and remove the diagnosis requirement for Bystolic.																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	Board Member Adashek moved to accept the proposed updates as presented.  Board Member Chu seconded the motion.  A vote was held: <table border="0" data-bbox="590 678 1522 1047"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
b. For Possible Action: Discussion and possible adoption of Genitourinary Agents - Bladder Antispasmodics.																																						
i. Public comment.	Telephonic and web comment was called for and the phone lines were opened.  No public comment was offered.																																					

Agenda Item	Record	Notes																																				
ii. Drug class review presentation by OptumRx.	<p>Dr. Jeffery discussed the Vesicare LS indication and the two clinical trials demonstrating efficacy over baseline.</p> <p>Dr. Jeffery recommended the Board consider the class clinically and therapeutically equivalent.</p>																																					
iii. Discussion by Board and action by Board to approve clinical/therapeutic equivalency of agents in class.	<p>Board Member Adashek moved to accept the class as clinically and therapeutically equivalent.</p> <p>Board Member Ward seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="590 630 1522 997"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Adashek, Joseph, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Chu, Evelyn, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Crumby, Mark, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Hautekeet, Mike, R.Ph</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Khurana, Sapandeep, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Passalacqua, Brian, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>Ward, Kate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Adashek, Joseph, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Chu, Evelyn, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Crumby, Mark, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Hautekeet, Mike, R.Ph	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Khurana, Sapandeep, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Passalacqua, Brian, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
Ward, Kate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
iv. Presentation of recommendations for PDL inclusion by OptumRx.	<p>Dr. Jeffery recommended adding Vesicare LS as non-preferred and keep the rest of the class the same.</p>																																					
v. Discussion by Board and action by Board for approval of drugs for inclusion on the PDL.	<p>Board Member Adashek moved to accept the recommendation.</p> <p>Board Member Chu seconded the motion.</p> <p>A vote was held:</p> <table border="0" data-bbox="590 1328 1522 1399"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>Decerbo, Mark, Pharm.D. – Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																													
	Yes	No	Abst.																																			
Decerbo, Mark, Pharm.D. – Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			

Agenda Item	Record	Notes
	<p>Adashek, Joseph, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Chu, Evelyn, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Crumby, Mark, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Hautekeet, Mike, R.Ph <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Khurana, Sapandeep, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Passalacqua, Brian, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p> <p>Ward, Kate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></p>	
<p>7. OptumRx Reports: New Drugs to Market and New Line Extensions</p>	<p>Dr. Jeffery discussed new treatments coming out for atopic dermatitis including abrocitinib, tralokinumab, and ruxolitinib and their respective expected indications and mechanisms of actions. Dr. Jeffery highlighted a new treatment for uterine fibroids containing relugolix, estradiol, and norethindrone. Dr. Jeffery identified generic pipeline medications, including Restasis, Byetta, Glucagon, intranasal Narcan, Bystolic, and Pradaxa, with their expected availability.</p>	
<p>8. Closing Discussion</p>		
<p>a. Public comments on any subject.</p>	<p>Telephonic and web comment was called for and the phone lines were opened.</p> <p>Comment was offered by Dylan Bassett, a Medical Science Liaison at Pierre Fabre Pharmaceuticals, regarding Hemangeol for the treatment of infantile proliferating hemangioma and asked the Board to consider adding Hemangeol to the preferred drug list. Mr. Bassett highlighted the incidence of infantile hemangioma and common consequences of non-treatment, the efficacy of Hemangeol in clinical trials, and side effects. Mr. Bassett again requested the Board to add Hemangeol as preferred since it is the only approved beta-blocker for the treatment of infantile hemangioma.</p> <p>Dr. Jeffery stated OptumRx will discuss this product and where it belongs on the preferred drug list and bring it back for discussion if appropriate.</p> <p>Board Member Adashek expressed concern about this medication being the only one for the treatment of infantile hemangioma.</p>	

Agenda Item	Record	Notes
	<p>Chairman Decerbo stated since it does have a unique indication it may be difficult to categorize with the other beta-blockers, but further investigation for placement is needed.</p> <p>No further public comment was offered.</p>	
<p>b. Date and location of the next meeting.</p>	<p>Chairman Decerbo confirmed the next meeting is scheduled for June 24, 2021, and will be a virtual meeting.</p>	
<p>c. Adjournment.</p>	<p>Chairman Decerbo adjourned the meeting at 2:19 PM.</p>	

## **Attachment A – Members of the Public in Attendance**

Bassett, Dylan, Pierre-Fabre

Berry, Kenneth

Binstock, Donalda

Colabianchi, Jeana, Sunovion

Cooper, Christa, Lilly

Droese, Ben, Amgen

Germain, Joe, Biogen

Gouchenour, Christie, Hometown Health

Hill, Laura, Abbvie

Kerr, Camille, Regeneron

Kohloff, Chi, Vielabio

Large, David

Leroue, Chelsea

McDermott, Lori, Supernus

Miglins, Margot, Amgen

Mobine, Hector

Oliver, Carmen, Biohaven Pharmaceuticals

Robinson, Lovell R, Abbvie

Sisco, Debra

Zarob, Michael

**Attachment B – Submitted Written Comment**

No written comment received.